Skip to search formSkip to main contentSkip to account menu

cositecan

Known as: (4S)-4-Ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H)-dione, Karenitecin 
A synthetic silicon-containing agent related to camptothecin with antineoplastic properties. Cositecan stabilizes the cleavable complex between… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BNP 1350

Broader (1)

Camptothecin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein
PurposeCamptothecins contain a lactone ring that is necessary for antitumor activity, and hydrolysis of the lactone ring yields… 
2008
2008
Phase II multicenter open‐label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
The topoisomerase I agents are established as a therapy in recurrent ovarian cancer. Karenitecin, an analog of topotecan with… 
2004
2004
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates
PurposeBNP1350 (7-[(2-trimethylsilyl)ethyl]-20(S)-camptothecin, karenitecin), a highly lipophilic camptothecin, a high percentage… 
2003
2003
Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.
PURPOSE 9-Aminocamptothecin colloidal dispersion (9-ACCD; NSC 603071) is a specific inhibitor of topoisomerase I that can be… 
2003
2003
Evaluation of In Vitro Drug Interactions with Karenitecin, a Novel, Highly Lipophilic Camptothecin Derivative in Phase II Clinical Development
The objective of this study was to describe the potential metabolism and protein‐binding interactions with karenitecin, a novel… 
2002
2002
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance
The novel camptothecin derivative BNP1350 (7‐[2‐trimethylsilyl)ethyl]‐20(S)‐camptothecin), also known as Karenitecin, has been… 
2002
2002
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
2001
2001
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice
Abstract.Purpose: Camptothecins have emerged as an important new class of antitumor drugs. Camptothecin derivatives such as CPT… 
2000
2000
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Cellular topoisomerase I is an important target in cancer chemotherapy. A novel karenitecin, BNP1350, is a topoisomerase I… 
1999
1999
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)